CLASH enables large-scale parallel knock-in for cell engineering

1. Dong, M. B. et al. Systematic immunotherapy target discovery using genome-scale in vivo CRISPR screens in CD8 T sells. Cell 178, 1189–1204.e1123 (2019).

   Article 
   CAS 
   
   Google Scholar 

2. Long, L. et al. CRISPR screens unveil signal hubs for nutrient licensing of T cell immunity. Nature 600, 308–313 (2021).

   Article 
   CAS 
   
   Google Scholar 

3. Chen, Z. et al. In vivo CD8⁺ T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell 184, 1262–1280.e1222 (2021). Refs. 1–3 are representative lentivirus-mediated CRISPR screens in primary T cells.

   Article 
   CAS 
   
   Google Scholar 

4. Roth, T. L. et al. Pooled knockin targeting for genome engineering of cellular immunotherapies. Cell 181, 728–744.e21 (2020). Mini-pool knock-in in human primary T cells.

   Article 
   CAS 
   
   Google Scholar 

5. Schumann, K. et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc. Natl Acad. Sci. USA 112, 10437–10442 (2015). CRISPR knock-in in human primary T cells.

   Article 
   CAS 
   
   Google Scholar 

Download references

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Dai, X. et al. Massively parallel knock-in engineering of human T cells. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01639-x (2023).